New data show pembrolizumab improves breast cancer outcomes regardless of age or menopausal status
New data from the KEYNOTE-756 phase 3 clinical trial show that adding the immunotherapy drug pembrolizumab to chemotherapy before and after surgery for breast cancer leads to better outcomes for patients regardless of their ...
Mar 19, 2024
0
1